ArticleGenes2026
Unveiling Disulfidptosis and Cuproptosis Vulnerabilities in Pterygium: A Transcriptomic Analysis and In-Silico Drug Repurposing Strategy.
Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPterygium is an invasive, hyperproliferative fibrovascular disorder of the ocular surface characterized by frequent postoperative recurrence and resistance to apoptosis. This study investigated transcriptional alterations in genes related to the regulated cell death pathways disulfidptosis and cuproptosis in pterygium and explored potential pharmacological candidates through in-silico drug repurposing.
methodsHigh-throughput RNA-sequencing data (GEO accession GSE155776) from primary pterygium tissues (
resultsTranscriptomic analysis demonstrated marked alterations in actin-cytoskeletal genes, with profound downregulation of
conclusionsPterygium is associated with coordinated transcriptional alterations involving disulfidptosis- and cuproptosis-related gene networks, suggesting potential structural and metabolic vulnerabilities. In-silico drug repurposing identified several pharmacological candidates whose transcriptional effects oppose the observed disease-associated signature. These findings provide a rationale for further experimental investigation of these pathways and candidate compounds in pterygium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.